Bayzed Health (02609.HK): Market Performance and Industry Opportunities Analysis of a New Force in Oncology Medical Services

Bayzed Health Group Inc. is a Chinese private oncology hospital group focusing on full-cycle oncology medical services [4]. The company was listed on the Main Board of the Hong Kong Stock Exchange on June 23, 2025, with the stock code 02609.HK [4]. As a leading private oncology medical service provider in China, its business focuses on oncology treatment solutions, which aligns with the development trend of the medical industry [4].

Bayzed Health has recently become a market hotspot, mainly due to the following factors:

1. Successful Listing
   : Listed on the Hong Kong Main Board on June 23, 2025, becoming a representative of newly listed medical stocks [4].
2. Favorable Industry Policies
   : Benefited from 2025 healthcare industry policies (such as support for innovative drugs, optimization of volume-based procurement, etc.) [6][7].
3. Overall Strength of the Sector
   : The healthcare sector performed strongly, and the industry’s investment value was recognized by the market [6].
4. Business Prospects
   : Focus on oncology medical services, which is in line with the industry development direction [4].
5. Significant Stock Price Rise
   : The stock price rose sharply from September to October 2025, with a maximum single-day gain of 28.03% [5].

The healthcare industry showed a good development trend in 2025, with innovative drug companies generally seeing growth in performance [7], and policy support increased [6]. As a new force in the oncology medical service field, Bayzed Health is expected to achieve rapid development by leveraging the industry’s momentum [1].